JUPITER NEUROSCIENCES, INC. Gain (Loss) on Derivative Instruments, Net, Pretax
JUPITER NEUROSCIENCES, INC. (JUNS) reported Gain (Loss) on Derivative Instruments, Net, Pretax of -$53.26 thousand for the 12-month period ending 2024-12-31, per its 10-K filed 2026-04-01.
Financial Statements › Income Statement › Other Income
us-gaap:GainLossOnDerivativeInstrumentsNetPretax · last filed 2026-04-01
- JUPITER NEUROSCIENCES, INC. gain (loss) on derivative instruments, net, pretax for the quarter ending 2024-12-31 was $0.00, a 100.00% decline year-over-year.
- JUPITER NEUROSCIENCES, INC. gain (loss) on derivative instruments, net, pretax for the quarter ending 2024-09-30 was $9.88K.
- JUPITER NEUROSCIENCES, INC. gain (loss) on derivative instruments, net, pretax for the quarter ending 2024-06-30 was -$25.43K.
- JUPITER NEUROSCIENCES, INC. gain (loss) on derivative instruments, net, pretax for the quarter ending 2024-03-31 was -$37.71K.
- JUPITER NEUROSCIENCES, INC. gain (loss) on derivative instruments, net, pretax for fiscal 2024 was -$53.26K, a 135.80% decline from fiscal 2023.
- JUPITER NEUROSCIENCES, INC. gain (loss) on derivative instruments, net, pretax for fiscal 2023 was $148.75K.
| Period end | Gain (Loss) on Derivative Instruments, Net, Pretax 3 month | Gain (Loss) on Derivative Instruments, Net, Pretax 6 month | Gain (Loss) on Derivative Instruments, Net, Pretax 9 month | Gain (Loss) on Derivative Instruments, Net, Pretax 12 month |
|---|---|---|---|---|
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-01 | $9.88K derived: sum of 2 quarters · filed 2026-04-01 | -$15.55K derived: sum of 3 quarters · filed 2026-04-01 | -$53.26K 10-K · filed 2026-04-01 |
| 2024-09-30 | $9.88K 10-Q · filed 2025-11-14 | -$15.55K derived: sum of 2 quarters · filed 2025-11-14 | -$53.26K 10-Q · filed 2025-11-14 | $110.95K derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | -$25.43K 10-Q · filed 2025-08-19 | -$63.14K 10-Q · filed 2025-08-19 | $101.07K derived: sum of 3 quarters · filed 2025-08-19 | $66.98K derived: sum of 4 quarters · filed 2025-08-19 |
| 2024-03-31 | -$37.71K 10-Q · filed 2025-05-15 | $126.50K derived: sum of 2 quarters · filed 2025-05-15 | $92.41K derived: sum of 3 quarters · filed 2025-05-15 | |
| 2023-12-31 | $164.21K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28 | $130.12K derived: sum of 2 quarters · filed 2025-03-28 | $148.75K 10-K · filed 2025-03-28 | |
| 2023-09-30 | -$34.09K 10-Q · filed 2024-12-23 | -$15.46K 10-Q · filed 2024-12-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |